[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625640":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":50,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CHM intervention group","EXPERIMENTAL",null,[13],"Drug: CHM intervention group",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group","Participants who do not receive the active CHM treatment during the study's initial phase (8 weeks) but are offered it after the trial ends.",[18],"Other: No CHM treatment",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Jia Wei Sheng Yu Si Ni Tang (JWSYSNT) powder, 4.5 gm per dose, taken orally 2 times a day, for 8 weeks",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"No CHM treatment","The waitlist control group received no JWSYSNT treatments and received no other intervention for 8 weeks after randomization.",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Ming-Yen Tsai, PhD","CONTACT","886-975-056534","missuriae@yahoo.com.tw",[35],{"facility":36,"status":11,"city":37,"state":11,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Chang Gung Memorial Hospital in Kaohsiung branch","Kaohsiung City","83301","Taiwan","TW",{"type":42,"coordinates":43},"Point",[44,45],120.31333,22.61626,{"lat":45,"lon":44},[48],{"name":30,"role":31,"phone":49,"phoneExt":11,"email":33},"+886-975-056534",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ming-Yen Tsai","Head of Chinese medicine","100625640","phase-2-a-pilot-trial-of-chinese-medicine-for-patients-with-dialytic-hypotension-100625640",false,"NCT07425262","A Pilot Trial of Chinese Medicine for Patients With Dialytic Hypotension","A Pilot Randomized Waitlist-controlled Trial of a Zheng-based Chinese Medicine Intervention for Patients With Dialytic Hypotension in Taiwan","Inclusion Criteria:\n\n* Maintenance bicarbonate hemodialysis (HD) for more than 1 year, three times a week 3.5 to 4.5 h HD schedule.\n* Have experienced more than 30% episodes of IDH (defined as a systolic BP\\\u003C90 mmHg on dialysis or requirement for clinical intervention) during the exposure assessment period (months 1-3) of this study\n* Cognitive ability to give written informed consent.\n\nExclusion Criteria:\n\n* Allergic history to Chinese herbal medicine\n* Systemic diseases such as coagulation disorders, malignancy, liver diseases and cardiovascular diseases.\n* Estimated survival time \\\u003C 1 year.\n* Mental illness.\n* Participate in other clinical trials.","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE2","PHASE3","To evaluate the epidemiological status of traditional Chinese Medicine (TCM) constitution in patients with dialytic hypotension, and design a clinical study based on a Zheng-based herbal formulation to evaluate the clinical efficacy and safety of TCM",[72,73],"End Stage Renal Disease on Dialysis","Intradialytic Hypotension","NOT_YET_RECRUITING","2026-02-23",{"date":77,"type":78},"2026-02-25","ACTUAL",{"date":80,"type":65},"2026-02-02",{"date":82,"type":65},"2028-02-01",{"name":5,"class":6},1]